Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 4, 2020- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness
MARBURG, Germany 4 September 2020 - CSL Behring a global biotherapeutics leader announced today that the company will host a symposium focused on the challenges of treating lung disease in the...
-
Jul 30, 2020• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.
Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...
-
Jul 9, 2020• Five coagulation researchers named this year’s recipients
KING OF PRUSSIA, Pa. – 9 July 2020 – Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Award for coagulation research just ahead of the...
-
Jul 6, 2020- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
KING OF PRUSSIA, Pa. – 6 July 2020 – Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy...
-
Jun 24, 2020• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
KING OF PRUSSIA, Pa., – 24 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an...
-
Jun 19, 2020
PHILADELPHIA--(June 19, 2020) – The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng,...
-
Jun 12, 2020Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...
-
Jun 8, 2020Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...
-
Jun 8, 2020• Builds on CSL Behring’s promise and commitment to the transplant community
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...
-
Jun 2, 2020Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)
SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...